Cargando…
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red blood cells by expressing c...
Autores principales: | Huang, Nai-Jia, Pishesha, Novalia, Mukherjee, Jean, Zhang, Sicai, Deshycka, Rhogerry, Sudaryo, Valentino, Dong, Min, Shoemaker, Charles B., Lodish, Harvey F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583347/ https://www.ncbi.nlm.nih.gov/pubmed/28871080 http://dx.doi.org/10.1038/s41467-017-00448-0 |
Ejemplares similares
-
Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity
por: Deshycka, Rhogerry, et al.
Publicado: (2021) -
A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding
por: Yao, Guorui, et al.
Publicado: (2017) -
Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function
por: Tremblay, Jacqueline M., et al.
Publicado: (2020) -
Structural characterisation of the catalytic domain of botulinum neurotoxin X - high activity and unique substrate specificity
por: Masuyer, Geoffrey, et al.
Publicado: (2018) -
Identification and characterization of a novel botulinum neurotoxin
por: Zhang, Sicai, et al.
Publicado: (2017)